XTend Medical (XMDC) Signs Exclusive Global Distribution Agreement With DDI
SUN VALLEY, Calif., Aug. 25 /PRNewswire-FirstCall/ — XTend Medical Corporation (Pink Sheets: XMDC), a company that delivers cutting-edge telemedicine solutions to the healthcare industry, has secured the exclusive global distribution rights to DDI’s Vibration Device for Pre-Screening of Diabetic Neuropathy.
The company released the following statement: “XTend Medical is pleased to announce that we have secured the global distribution rights to DDI’s patented vibration technology device, now in its fourth generation. Once the FDA has cleared the device for sale, we will immediately begin marketing the product to our managed care companies and the various physicians and patients here in the U.S. We’re also in negotiations to market the product in South Korea and Europe based on their separate criteria needs for final approval. Once these are received, then we’ll target these markets heavily. Although the device can pre-screen people that may have diabetic neuropathy, the first signs that diabetes may be present, it also assists the current diabetic patient with monitoring their neuropathy levels so their disease is managed correctly. We anticipate this device to bring in additional sales upwards of $5 million per year in the U.S. and possibly three times that amount globally,” stated Mr. Paul D. Lisenby, CEO of XTend Medical.
For any healthcare agency or physician group that would like to find out more about how XTend can assist in your management of diabetic patients, please visit the company website at http://www.xtendmedical.com/ or email us at email@example.com
About XTend Medical: XTend Medical Corporation markets and sells healthcare and wellness products to hospitals, managed care companies, nursing homes, physician groups and individual patients. XTend has developed a complete Remote Diabetic Patient Monitoring System that is currently being used by physicians and other healthcare agencies throughout the U.S. Through their alliances, XTend offers pharmacy services, diabetic supplies, and telemedicine products that increase patient care yet reduce costs associated with servicing those patients. For more information, please visit their website at http://www.xtendmedical.com
This press release contains or may contain forward-looking statements such as statements regarding the Company’s growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.
Contact: Company Contact: FutureTechIR for XTend Medical Corporation Investor Relations (817) 812-2105
XTend Medical Corporation
CONTACT: FutureTechIR, Investor Relations, +1-817-812-2105, for XTendMedical Corporation
Web site: http://www.xtendmedical.com/